Intercept Pharmaceuticals (ICPT) Prices IPO at $15 Per Share
Tweet Send to a Friend
Up)
Intercept Pharmaceuticals, Inc., (Nasdaq: ICPT) a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases, today announced the pricing of its initial public offering of 5,000,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. All of the common stock is being offered by Intercept.
In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. The Company's shares are expected to begin trading on The NASDAQ Global Market on Thursday, October 11, 2012 under the trading symbol (Nasdaq: ICPT).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
In addition, the underwriters have a 30-day option to purchase up to an additional 750,000 shares of common stock from Intercept. The Company's shares are expected to begin trading on The NASDAQ Global Market on Thursday, October 11, 2012 under the trading symbol (Nasdaq: ICPT).
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Intercept Pharmaceuticals Announces Positive Initial Results from Ongoing Phase 2a Trial in Chronic Bile Acid Diarrhea
- William Lyon Homes (WLH) IPO Opens 8% Higher
- Tableau Software (DATA) IPO now indicated $45-$48
Create E-mail Alert Related Categories
IPOs
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
